Teladoc Health Appoints Independent Director Mark Anquillare

What Happened
Teladoc Health, Inc. (TDOC) filed an 8‑K reporting that on August 3, 2026 the Board increased its size to ten directors and appointed Mark V. Anquillare as a director. Mr. Anquillare was also named to the Board’s audit committee and compensation committee. The Board determined he is an independent director under NYSE standards and an “audit committee financial expert” under SEC and NYSE rules. The company issued a press release on August 3, 2026 regarding the appointment.

Key Details

• Effective date: August 3, 2026.
• Board size increased to 10 directors with Mr. Anquillare’s appointment.
• Committee assignments: audit committee and compensation committee.
• Board determined Mr. Anquillare is independent and an SEC/NYSE “audit committee financial expert.”
• Company reports no related-party transactions required to be disclosed under Item 404(a) of Regulation S-K.
• Mr. Anquillare will have the same director indemnification arrangement as directors appointed since October 2020 and is eligible for the Company’s non‑employee director compensation programs (as described in the April 7, 2026 proxy).

Why It Matters
This filing updates Teladoc’s board composition and governance oversight. Adding an independent director who is designated an audit committee financial expert may strengthen financial oversight and reporting oversight, while changes to committee membership can affect how the company reviews financial controls and executive pay. The absence of reportable related‑party transactions and the standard indemnification/compensation arrangements reduce immediate governance risk for investors.